WALTHAM, Mass.--(BUSINESS WIRE)--
PerkinElmer,
Inc. (NYSE: PKI), a global leader focused on improving the health
and safety of people and the environment, today announced that the
Company has completed its acquisition of Caliper
Life Sciences, Inc. (NASDAQ: CALP), a Hopkinton, Massachusetts-based
leader in imaging and detection solutions for life sciences research,
diagnostics and environmental markets. In September, PerkinElmer
announced its intent to acquire Caliper for $10.50 per share, for a
total net purchase price of approximately $600 million in cash.
Robert F. Friel, chairman and chief executive officer, PerkinElmer,
said, "The integration of Caliper into our organization will further
strengthen PerkinElmer's position in personalized medicine. The
acquisition will enhance our ability to provide customers with the
complementary technologies, services and knowledge they need to drive
innovation from in vivo to in vitro imaging, and provide
expanded offerings across our biomedical, diagnostics, environmental and
food safety end-markets."
Friel added, "I am also very pleased to welcome Kevin Hrusovsky, who was
Caliper's CEO, to PerkinElmer. Kevin will lead a newly combined $500
million business, which integrates the former Caliper organization with
PerkinElmer's existing research business. Kevin's deep industry
expertise and successful track record in leading Caliper will provide
PerkinElmer with an even stronger foundation as we help customers to
develop life-saving and enhancing diagnostics and therapeutics."
Kevin Hrusovsky said, "We are very excited about the opportunities ahead
of us following the combination of two highly successful businesses. Our
shared vision for giving customers the tools and insights they need to
understand the origins of disease, create new therapies, and transform
personalized medicine, is a compelling road map for success as we move
forward together."
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share, cash flow and revenue growth
and other financial results, developments relating to our customers and
end-markets, and plans concerning business development opportunities and
divestitures. Words such as "believes," "intends," "anticipates,"
"plans," "expects," "projects," "forecasts," "will" and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's
current assumptions and expectations and no assurances can be given that
our assumptions or expectations will prove to be correct. A number of
important risk factors could cause actual results to differ materially
from the results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) markets into
which we sell our products declining or not growing as anticipated; (2)
fluctuations in the global economic and political environments; (3) our
failure to introduce new products in a timely manner; (4) our ability to
execute acquisitions and license technologies, or to successfully
integrate acquired businesses and licensed technologies into our
existing business or to make them profitable, or successfully divest
businesses; (5) our failure to adequately protect our intellectual
property; (6) the loss of any of our licenses or licensed rights; (7)
our ability to compete effectively; (8) fluctuation in our quarterly
operating results and our ability to adjust our operations to address
unexpected changes; (9) significant disruption in third-party package
delivery and import/export services or significant increases in prices
for those services; (10) disruptions in the supply of raw materials and
supplies; (11) the manufacture and sale of products exposing us to
product liability claims; (12) our failure to maintain compliance with
applicable government regulations; (13) regulatory changes; (14) our
failure to comply with healthcare industry regulations; (15) economic,
political and other risks associated with foreign operations; (16) our
ability to retain key personnel; (17) significant disruption in our
information technology systems; (18) our ability to obtain future
financing; (19) restrictions in our credit agreements; (20) our ability
to realize the full value of our intangible assets; (21) significant
fluctuations in our stock price; (22) reduction or elimination of
dividends on our common stock; and (23) other factors which we describe
under the caption "Risk Factors" in our most recent quarterly report on
Form 10-Q and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $1.7 billion in 2010, has about 7,000 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
PerkinElmer, Inc.
Investor Relations:
David C.
Francisco, 781-663-5677
Vice President, Investor Relations
dave.francisco@perkinelmer.com
or
Media
Contacts:
Stephanie R. Wasco, 781-663-5701
Vice President,
Corporate Communications
stephanie.wasco@perkinelmer.com
or
Mario
Fante, 781-663-5602
Corporate Public Relations Manager
mario.fante@perkinelmer.com
Source: PerkinElmer, Inc.
News Provided by Acquire Media